Ondine Biomedical Inc Asset Resilience Ratio

Latest as of September 2008: 39.85%

Ondine Biomedical Inc asset resilience ratio. Ondine Biomedical Inc (OBI) has an Asset Resilience Ratio of 39.85% as of September 2008. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Ondine Biomedical Inc to measure how many days the company can operate on defensive assets alone.

Liquid Assets

GBX1.88 Million
≈ $228.22 USD Cash + Short-term Investments

Total Assets

GBX4.71 Million
≈ $572.65 USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Ondine Biomedical Inc (2006–2007)

Asset resilience ratio of Ondine Biomedical Inc from 2006 to 2007. This chart shows how Ondine Biomedical Inc's Asset Resilience Ratio has changed over time. Read how much debt does Ondine Biomedical Inc carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Ondine Biomedical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OBI total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX1.88 Million 39.85%
Total Liquid Assets GBX1.88 Million 39.85%

Asset Resilience Insights

  • Very High Liquidity: Ondine Biomedical Inc maintains exceptional liquid asset reserves at 39.85% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Ondine Biomedical Inc Industry Peers by Asset Resilience Ratio

Compare Ondine Biomedical Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Samsung Biologics Co Ltd
KO:207940
Biotechnology 15.21%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
Biotechnology 5.07%
Immunovant Inc
NASDAQ:IMVT
Biotechnology 98.50%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Amicus Therapeutics Inc
NASDAQ:FOLD
Biotechnology 8.37%

Ondine Biomedical Inc Asset Resilience Ratio by Year (2006–2007)

Ondine Biomedical Inc asset resilience ratio by year from 2006 to 2007. The table below shows the annual Asset Resilience Ratio data for Ondine Biomedical Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2007-12-31 43.12% GBX5.61 Million
≈ $682.19
GBX13.00 Million
≈ $1.58K
-15.66pp
2006-12-31 58.78% GBX10.85 Million
≈ $1.32K
GBX18.46 Million
≈ $2.25K
--
pp = percentage points

About Ondine Biomedical Inc

LSE:OBI UK Biotechnology
Market Cap
$614.56K
GBX5.05 Billion GBX
Market Cap Rank
#30957 Global
#885 in UK
Share Price
GBX9.00
Change (1 day)
-4.76%
52-Week Range
GBX8.00 - GBX15.40
All Time High
GBX58.50
About

Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfecti… Read more